2. Academic Validation
  3. Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy

Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy

  • Cell Stem Cell. 2025 Jul 3;32(7):1087-1101.e4. doi: 10.1016/j.stem.2025.05.007.
Martin P Hosking 1,  Soheila Shirinbak 2,  Kyla Omilusik 2,  Shilpi Chandra 2,  Mika K Kaneko 3,  Angela Gentile 2,  Susumu Yamamoto 4,  Bishwas Shrestha 2,  Joy Grant 2,  Megan Boyett 2,  Demetrio Cardenas 2,  Hannah Keegan 2,  Samad Ibitokou 2,  Carolina Pavon 2,  Takahiro Mizoguchi 4,  Tatsuya Ihara 4,  Daisuke Nakayama 4,  Ramzey Abujarour 2,  Tom T Lee 2,  Raedun Clarke 2,  Jode Goodridge 2,  Eigen Peralta 2,  Tatsuo Maeda 4,  Junichi Takagi 5,  Takao Arimori 5,  Yukinari Kato 3,  Bahram Valamehr 6
Affiliations

Affiliations

  • 1 Fate Therapeutics, Inc., San Diego, CA, USA. Electronic address: martin.hosking@fatetherapeutics.com.
  • 2 Fate Therapeutics, Inc., San Diego, CA, USA.
  • 3 Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Miyagi, Japan.
  • 4 Minase Research Institute, Ono Pharmaceutical Co., Ltd., Osaka, Japan.
  • 5 Institute for Protein Research, Osaka University, 3-2, Yamadaoka, Suita 565-0871, Osaka, Japan.
  • 6 Fate Therapeutics, Inc., San Diego, CA, USA. Electronic address: bob.valamehr@fatetherapeutics.com.
PMID: 40472844 DOI: 10.1016/j.stem.2025.05.007
Abstract

Chimeric antigen receptor (CAR) T cell therapies in solid tumors have been limited by on-target, off-tumor toxicity, antigen heterogeneity, and an inability to simultaneously overcome multiple diverse resistance mechanisms within the tumor microenvironment that attenuate anti-tumor activity. Here, we describe an induced pluripotent stem cell (iPSC)-derived CAR T cell that combines a human epidermal growth factor receptor 2 (HER2)-targeting CAR-differentially recognizing tumor from normal cells and enabling detection of both truncated and misfolded HER2-with multiplex editing designed to address and overcome obstacles to maximize efficacy in solid tumor indications. The iPSC-derived, HER2-directed CAR T cells maintained potent HER2-specific anti-tumor activity in both in vitro and in vivo settings, with limited cytolytic targeting of HER2+ normal targets. Combination with therapeutic antibodies enabled comprehensive multi-antigen targeting through both the CAR and a high-affinity, non-cleavable CD16a Fc receptor. Additionally, specific engineering of interleukin (IL)-7R-fusion, transforming growth factor β (TGF-β)-IL-18R, and CXCR2 enabled sustained persistence, resistance to TGF-β-mediated suppression, and specific migration to the tumor.

Keywords

CAR T; HER2; TGF-β; antibody-dependent cellular cytotoxicity; iPSC; solid tumor; trafficking.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z